PT Inquest is an online journal club. Hosted by Jason Tuori, Megan Graham, and Chris Juneau, the show looks at an article every week and discusses how it applies to current physical therapy practice.
…
continue reading
コンテンツは Behind The Knife: The Surgery Podcast によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Behind The Knife: The Surgery Podcast またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作権で保護された作品をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!
Player FMアプリでオフラインにしPlayer FMう!
Journal Review in Thoracic Surgery: Adjuvant Therapy in Lung Adenocarcinoma
Manage episode 307710227 series 120340
コンテンツは Behind The Knife: The Surgery Podcast によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Behind The Knife: The Surgery Podcast またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作権で保護された作品をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
November is Lung Cancer Awareness Month, and what better way is there to spend your time than getting to know the recent advances in adjuvant therapy for early-stage lung adenocarcinoma?
Learning Objectives
- Review work-up and treatment of lung adenocarcinoma
- Review evidence behind Osimertinib as an adjuvant therapy in EGFR mutation positive disease
- Review recent advances in gene expression profiles for targeted application of adjuvant chemotherapy
- Discuss future directions for research
- Discuss additional advancements in diagnosis, monitoring, and immunotherapy
Referenced Material
- Wu Y, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020; 383:1711-1723. DOI: 10.1056/NEJMoa2027071 https://www.nejm.org/doi/full/10.1056/NEJMoa2027071
- Woodard GA, Wang SX, Kratz JR, et al. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer 2018;19(1):58-64. DOI: 10.1016/j.cllc.2017.05.015
https://www.clinical-lung-cancer.com/article/S1525-7304(17)30150-X/fulltext
- Woodard GA, Kratz JR, Haro G, et al. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clin Lung Cancer. 2021;20:S1525-7304(21)00212-6. DOI: 10.1016/j.cllc.2021.08.008
https://www.clinical-lung-cancer.com/article/S1525-7304(21)00212-6/fulltext
Please visit behindtheknife.org to access other high-yield surgical education podcasts, videos and more.
Learning Objectives
- Review work-up and treatment of lung adenocarcinoma
- Review evidence behind Osimertinib as an adjuvant therapy in EGFR mutation positive disease
- Review recent advances in gene expression profiles for targeted application of adjuvant chemotherapy
- Discuss future directions for research
- Discuss additional advancements in diagnosis, monitoring, and immunotherapy
Referenced Material
- Wu Y, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020; 383:1711-1723. DOI: 10.1056/NEJMoa2027071 https://www.nejm.org/doi/full/10.1056/NEJMoa2027071
- Woodard GA, Wang SX, Kratz JR, et al. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer 2018;19(1):58-64. DOI: 10.1016/j.cllc.2017.05.015
https://www.clinical-lung-cancer.com/article/S1525-7304(17)30150-X/fulltext
- Woodard GA, Kratz JR, Haro G, et al. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clin Lung Cancer. 2021;20:S1525-7304(21)00212-6. DOI: 10.1016/j.cllc.2021.08.008
https://www.clinical-lung-cancer.com/article/S1525-7304(21)00212-6/fulltext
Please visit behindtheknife.org to access other high-yield surgical education podcasts, videos and more.
692 つのエピソード
Manage episode 307710227 series 120340
コンテンツは Behind The Knife: The Surgery Podcast によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Behind The Knife: The Surgery Podcast またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作権で保護された作品をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
November is Lung Cancer Awareness Month, and what better way is there to spend your time than getting to know the recent advances in adjuvant therapy for early-stage lung adenocarcinoma?
Learning Objectives
- Review work-up and treatment of lung adenocarcinoma
- Review evidence behind Osimertinib as an adjuvant therapy in EGFR mutation positive disease
- Review recent advances in gene expression profiles for targeted application of adjuvant chemotherapy
- Discuss future directions for research
- Discuss additional advancements in diagnosis, monitoring, and immunotherapy
Referenced Material
- Wu Y, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020; 383:1711-1723. DOI: 10.1056/NEJMoa2027071 https://www.nejm.org/doi/full/10.1056/NEJMoa2027071
- Woodard GA, Wang SX, Kratz JR, et al. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer 2018;19(1):58-64. DOI: 10.1016/j.cllc.2017.05.015
https://www.clinical-lung-cancer.com/article/S1525-7304(17)30150-X/fulltext
- Woodard GA, Kratz JR, Haro G, et al. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clin Lung Cancer. 2021;20:S1525-7304(21)00212-6. DOI: 10.1016/j.cllc.2021.08.008
https://www.clinical-lung-cancer.com/article/S1525-7304(21)00212-6/fulltext
Please visit behindtheknife.org to access other high-yield surgical education podcasts, videos and more.
Learning Objectives
- Review work-up and treatment of lung adenocarcinoma
- Review evidence behind Osimertinib as an adjuvant therapy in EGFR mutation positive disease
- Review recent advances in gene expression profiles for targeted application of adjuvant chemotherapy
- Discuss future directions for research
- Discuss additional advancements in diagnosis, monitoring, and immunotherapy
Referenced Material
- Wu Y, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020; 383:1711-1723. DOI: 10.1056/NEJMoa2027071 https://www.nejm.org/doi/full/10.1056/NEJMoa2027071
- Woodard GA, Wang SX, Kratz JR, et al. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer 2018;19(1):58-64. DOI: 10.1016/j.cllc.2017.05.015
https://www.clinical-lung-cancer.com/article/S1525-7304(17)30150-X/fulltext
- Woodard GA, Kratz JR, Haro G, et al. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clin Lung Cancer. 2021;20:S1525-7304(21)00212-6. DOI: 10.1016/j.cllc.2021.08.008
https://www.clinical-lung-cancer.com/article/S1525-7304(21)00212-6/fulltext
Please visit behindtheknife.org to access other high-yield surgical education podcasts, videos and more.
692 つのエピソード
すべてのエピソード
×プレーヤーFMへようこそ!
Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。